Caligan Partners increased its interest in Liquidia, a cardiopulmonary-disease-focused pharmaceutical firm, to 10,360,945 shares. This excludes shares associated with founder David Johnson, who serves on Liquidia’s board. Caligan acquired 1,117,318 Liquidia shares through a Dec. 14 offering priced at $7.16 each.
After the offering’s close, Caligan now owns 15.1% of Liquidia’s outstanding stock. So far this year, Liquidia stock has seen a significant gain of nearly 68%.
Decreases in Holdings
Janus International Group
Clearlake Capital liquidated its stake in Janus International, a commercial door and self-storage unit maker. On Dec. 14, Clearlake Capital sold 23,044,110 Janus International shares at a price of $10.01 each as settlement for a post-paid-forward transaction. Additionally, Clearlake Capital sold 26,548 Janus International shares on the open market on Dec. 15 at prices ranging from $11.83 to $11.87 per share. Apart from 15,306 restricted units held by Clearlake Capital founder Jose Feliciano, who is the chairman of Janus International, Clearlake is no longer a shareholder in the industrial firm.
Janus International's shares have experienced a year-to-date gain of approximately 29%.
Elliott Management Reduces Stake in Coal Producer
Elliott Management has sold a portion of its stake in Peabody Energy, bringing its ownership down to 14,975,000 shares. The sale, which took place from December 6th to December 15th, saw Elliott sell 2,975,000 shares at prices ranging from $23.35 to $23.94 each. This follows a previous sale in mid-November through December 1st, where Elliott sold 3,159,807 shares at similar prices. Currently, Elliott holds 11.4% of Peabody Energy's outstanding shares. The stock has seen a 7.1% decrease in value this year.
OrbiMed Advisors Reduces Position in Clinical-Stage Pharmaceutical Firm
OrbiMed Advisors has cut its position in Disc Medicine to 1,702,237 shares. The sale, which took place from December 12th to December 14th, saw OrbiMed sell 567,400 shares at per share prices between $56.75 and $60.16. OrbiMed now owns 7.1% of the pharmaceutical company's tradable stock.
So far this year, Disc Medicine's stock has seen an impressive gain of approximately 187%. This increase can be attributed to significant progress in the company's drug pipeline. Notable advances include the FDA granting fast track status to its treatment for polycythemia vera, a blood cancer, in September. Additionally, this month marked Disc's presentation of results from its Phase 2 trial for bitopertin, a treatment for the rare metabolic disorder erythropoietic protoporphyria.
ASP BB Holdings Reduces Stake in Bus Manufacturing Company
ASP BB Holdings has significantly reduced its stake in Blue Bird to 4,042,650 shares. The reduction came as ASP sold 2.5 million Blue Bird shares through an offering on December 19th, with the shares priced at $25.10 each. This offering follows previous sales, including one in September 2023 where ASP sold 1,262,500 shares priced at $21 per share, and another in June 2023 where ASP sold 1,725,000 shares at $20 per share. Currently, ASP owns 12.6% of Blue Bird's outstanding stock.
So far this year, Blue Bird's stock has seen a substantial gain of roughly 140%.